Skip to main content

Endometrial Cancer Screening

Unlike breast or cervical cancer, no routine screening is recommended for endometrial cancer in average-risk individuals by any major guideline organization — including the ACS, ACOG, NCCN, and AAFP.[1][2][3] The cornerstone of early detection remains symptom awareness and prompt evaluation of abnormal uterine bleeding, particularly postmenopausal bleeding. Screening is considered only in specific high-risk hereditary cancer syndromes, and even in those populations, evidence of a mortality benefit from surveillance is lacking. Urogynecologists and pelvic reconstructive surgeons are frequently positioned to counsel patients about these screening principles, particularly women with Lynch syndrome undergoing risk-reducing surgery counseling, patients on tamoxifen, or those presenting with pelvic symptoms that require workup.

All major societies agree that evidence is insufficient to recommend screening for endometrial cancer in average-risk women, including those with common risk factors such as obesity, tamoxifen use, late menopause, nulliparity, or diabetes.[1][3]

The primary recommendation is patient education: at the onset of menopause, all individuals with a uterus should be informed about the risks and symptoms of endometrial cancer and strongly encouraged to report any unexpected vaginal bleeding or spotting immediately.[4][1] This approach is supported by the fact that 75–90% of endometrial cancers present with abnormal vaginal bleeding, and most are diagnosed at an early stage with favorable prognosis.[5][3]

Why population-based screening has not been adopted​

Several factors explain the absence of a population-level screening program:[2][6]

Favorable natural history. Most endometrial cancers present symptomatically at stage I, with 5-year survival rates exceeding 88%. Demonstrating a mortality benefit from screening in a generally good-prognosis cancer is inherently difficult.[2][7]

Transvaginal ultrasound (TVUS) limitations. TVUS has insufficient diagnostic accuracy for asymptomatic screening. At a 5-mm endometrial thickness cutoff in postmenopausal women, sensitivity is ~90–97% but specificity is only ~35–62%, leading to high false-positive rates and unnecessary invasive procedures. TVUS is not recommended for premenopausal screening due to normal cyclical variation in endometrial thickness.[6][2][8][3]

Endometrial biopsy is invasive. While highly sensitive and specific for diagnosis, endometrial biopsy is too invasive for population-based screening. Inadequate sample rates range from 7–40% in postmenopausal women.[9]

No proven mortality reduction. No screening modality has demonstrated a reduction in endometrial cancer mortality in any population studied, including high-risk groups.[2][10]

Diagnostic evaluation of symptomatic patients​

While not screening, the workup for symptomatic patients is foundational to clinical practice:

  • TVUS is the recommended initial approach (per ACOG) for postmenopausal women with a single episode of vaginal bleeding. An endometrial thickness ≤4 mm has a >99% negative predictive value for endometrial cancer.[5]
  • A retrospective study of 1,494 Black women reported a 9.5% false-negative rate at the 4-mm threshold, raising concerns about racial disparities in diagnostic accuracy.[5]
  • Persistent or recurrent bleeding warrants histologic evaluation (endometrial biopsy) regardless of endometrial thickness, as aggressive subtypes cannot be excluded by thickness alone.[5]
  • Pipelle endometrial biopsy is the preferred office-based diagnostic procedure, with sensitivity of 75–100% and ~100% specificity for endometrial cancer.[3][9]
  • In premenopausal women, TVUS has no diagnostic value for abnormal bleeding; endometrial biopsy should be performed based on risk factors and clinical judgment.[5][3]

High-risk populations: hereditary cancer syndromes​

Surveillance is considered only in specific hereditary syndromes, though evidence of mortality benefit remains limited.

Lynch syndrome​

Lynch syndrome (LS) confers a 30–50% lifetime risk of endometrial cancer — the most common extraintestinal sentinel cancer in LS.[5][2] Risk varies by gene. NCCN Genetic/Familial High-Risk Assessment (Colorectal, Endometrial, and Gastric) provides gene-specific surveillance recommendations:[8]

GeneApprox. lifetime EC riskSurveillance start ageRecommendation
MLH125–60%30–35Annual endometrial biopsy ± TVUS (TVUS not preferred); discuss risk-reducing hysterectomy
MSH225–60%30–35Same as MLH1
MSH625–71%30–35Same; higher absolute risk warrants lower threshold for surgical discussion
PMS215–20%30–35Consider annual endometrial sampling; lower-risk gene but surveillance is reasonable
EPCAMSimilar to MLH1/MSH230–35Depends on deletion extent; manage similar to MLH1/MSH2

Critical NCCN caveats for all LS genes:[8]

  • EC screening does not have proven benefit in LS patients. However, endometrial biopsy is both highly sensitive and specific as a diagnostic procedure and can be considered.
  • TVUS is not recommended as a screening tool in premenopausal patients. In postmenopausal patients, TVUS has not been shown to be sufficiently sensitive or specific to support a positive recommendation, but may be considered at clinician discretion.
  • Symptom education is paramount — patients must be counseled to report any abnormal uterine or postmenopausal bleeding promptly.
  • Total hysterectomy has not been shown to reduce EC mortality, but reduces EC incidence and is a legitimate risk-reducing option to discuss after completion of childbearing.

ACOG Practice Bulletin No. 147 similarly recommends endometrial biopsy every 1–2 years starting at age 30–35 for LS carriers, noting that TVUS has poor sensitivity and specificity in this population.[10] The US Multi-Society Task Force on Colorectal Cancer concurs with annual pelvic examination and endometrial sampling starting at age 30–35 (level V evidence, GRADE low quality).[7]

Cowden syndrome (PTEN hamartoma tumor syndrome)​

Individuals with Cowden syndrome have a 5–22% lifetime risk of endometrial cancer.[5] Per NCCN Genetic/Familial High-Risk Assessment (Breast, Ovarian, Pancreatic, and Prostate):[11]

  • Consider endometrial cancer screening starting by age 35
  • Endometrial biopsy every 1–2 years can be considered
  • TVUS carries the same limitations as in LS
  • Discuss hysterectomy upon completion of childbearing (oophorectomy is not indicated for Cowden syndrome alone)

Other hereditary cancer syndromes​

The ACS also recommends considering annual endometrial testing starting at age 35 for women with a substantial likelihood of carrying a Lynch syndrome mutation or families with suspected autosomal dominant predisposition to colorectal cancer, even without confirmed genetic testing.[1]

Risk factors​

Risk factorRelative riskNotes
Obesity (BMI ≥30)2–4×Accounts for up to 50% of EC cases; BMI ≥40 associated with RR ~6×[16][3]
Unopposed estrogen therapy4–8×Markedly attenuated by progestogen opposition[12]
Tamoxifen use2–3×Standard 20 mg/day; aggressive subtypes not clearly increased at standard dose[23]
Late menopause (≥55 years)~2×Prolonged estrogen exposure[12]
Nulliparity~2×Each pregnancy reduces risk ~25%[5]
Diabetes / insulin resistance2×Independent of obesity[12]
Lynch syndrome30–50% lifetimeGene-specific (see table above)[5]
Cowden syndrome5–22% lifetimePTEN mutation[11]
Prior pelvic irradiationIncreasedAssociated with higher-grade tumors[3]
PCOS / chronic anovulation~3×Prolonged unopposed estrogen[12]

Protective factors: combined oral contraceptives (30–50% risk reduction with ≥10 years of use, persisting 30+ years after cessation); progesterone-containing IUDs (pooled OR 0.81); parity; and physical activity.[12][5][2]

Risk reduction strategies​

Hormonal and pharmacologic​

  • Combined oral contraceptives: 10 years of use reduces absolute EC risk before age 75 from 2.3 to 1.3 per 100 women. In LS, OCPs decrease epithelial proliferation and produce inactive/secretory histology, though direct cancer-risk-reduction data are limited.[5][13]
  • Levonorgestrel IUS (Mirena): Associated with lower EC risk (OR 0.81) and is used for chemoprevention in high-risk women and for fertility-sparing treatment of atypical hyperplasia / early EC.[5][2][14]
  • Aspirin: The CAPP2 trial in Lynch syndrome found fewer endometrial cancers with aspirin vs. placebo (7 vs. 17 cases; HR 0.50, 95% CI 0.22–1.11), though underpowered for this endpoint. A pooled analysis of 7,120 EC cases found weekly aspirin use was associated with ~15% reduced risk in overweight/obese women (OR 0.86), with no association in normal-weight women.[2][15]
  • Metformin: Theoretical value through insulin sensitization, but no prospective trial data yet support primary prevention use.[2]

Surgical​

  • Risk-reducing hysterectomy is the most definitive prevention strategy for LS carriers. Timing is individualized by gene, family history, and reproductive goals (see Lynch syndrome table above).[8]
  • Bariatric surgery in obese women is associated with a significant reduction in EC risk (OR 0.32 in a systematic review).[5]

Lifestyle​

Weight management is the most impactful modifiable intervention. Obesity accounts for up to 50% of endometrial cancers in some estimates. Physical activity independently reduces risk beyond weight loss alone.[16][3]

Tamoxifen-specific considerations​

Per ACOG, routine endometrial screening is not recommended for asymptomatic women on tamoxifen at the standard 20 mg/day dose.[23]

  • The 2–3× increased relative risk does not justify routine screening given the low absolute risk
  • Any abnormal vaginal bleeding in a tamoxifen user should be promptly evaluated
  • Endometrial polyps, hyperplasia, and cancer can all occur; stage and grade of tamoxifen-associated EC at standard doses are similar to sporadic EC
  • Higher doses (40 mg/day) may be associated with more biologically aggressive tumors[23]

Emerging screening technologies​

No novel screening tool is currently recommended for clinical use, but several approaches show promise:[2][17][18]

  • DNA methylation markers from cervicovaginal samples: The WID-qEC test (assessing methylation of ZSCAN12 and GYPC) was validated in a prospective UK cohort and compared favorably with sonography for detecting uterine cancers in women with abnormal bleeding (EPI-SURE study).[6] A separate three-gene methylation panel (ZNF626, GRIA4, SPDYA) from cervical cytology samples achieved 92.86% detection of stage I EC in a validation cohort.[19]
  • Liquid biopsy: Serum exosomal piRNA panels and plasma-derived exosomal miRNAs (e.g., miR-15a-5p) have shown AUCs of 0.81–0.94 for EC detection in early studies.[20][21]
  • Protein biomarkers: HE4 remains the best available serum biomarker but has limited discrimination (AUC ~0.76 within 12 months of diagnosis); combining it with additional proteins has not improved performance meaningfully.[22]
  • Integration with cervical cancer screening: DNA methylation testing from routine Pap smear samples could potentially be incorporated into existing cervical screening infrastructure, transforming EC detection without a separate screening visit.[18][19]

These technologies remain investigational and require prospective validation before clinical implementation.

Cross-references​

References​

1. Smith RA, Andrews KS, Brooks D, et al. "Cancer Screening in the United States, 2019: A Review of Current American Cancer Society Guidelines and Current Issues in Cancer Screening." CA Cancer J Clin. 2019;69(3):184–210. doi:10.3322/caac.21557

2. Crosbie EJ, Kitson SJ, McAlpine JN, et al. "Endometrial Cancer." Lancet. 2022;399(10333):1412–1428. doi:10.1016/S0140-6736(22)00323-3

3. Bryce C, Gazda R, Fuerst H. "Endometrial Cancer: Rapid Evidence Review." Am Fam Physician. 2025;111(6):526–531.

4. American Cancer Society. "American Cancer Society Guidelines for the Early Detection of Cancer." American Cancer Society; 2023. https://www.cancer.org

5. Mager KL, McLean K. "Endometrial Cancer." JAMA. 2026. doi:10.1001/jama.2026.2248

6. Evans I, Reisel D, Jones A, et al. "Performance of the WID-qEC Test Versus Sonography to Detect Uterine Cancers in Women With Abnormal Uterine Bleeding (EPI-SURE): A Prospective, Consecutive Observational Cohort Study in the UK." Lancet Oncol. 2023;24(12):1375–1386. doi:10.1016/S1470-2045(23)00466-7

7. Giardiello FM, Allen JI, Axilbund JE, et al. "Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer." Gastroenterology. 2014;147(2):502–526. doi:10.1053/j.gastro.2014.04.001

8. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. Updated 2025-06-13. https://www.nccn.org

9. Vikram SR, Robinson J, Thanawala T, et al. "Ultrasound and Blind Endometrial Sampling for Detection of Endometrial Cancer in Women With Postmenopausal Bleeding." Cochrane Database Syst Rev. 2024;6:CD014568. doi:10.1002/14651858.CD014568

10. American College of Obstetricians and Gynecologists. "ACOG Practice Bulletin No. 147: Lynch Syndrome." Obstet Gynecol. 2014;124(5):1042–1054. doi:10.1097/01.AOG.0000456325.50739.72

11. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Updated 2026-02-19. https://www.nccn.org

12. Lu KH, Broaddus RR. "Endometrial Cancer." N Engl J Med. 2020;383(21):2053–2064. doi:10.1056/NEJMra1514010

13. Chen LM, Blank SV, Burton E, et al. "Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review." Fertil Steril. 2019;112(6):1034–1042. doi:10.1016/j.fertnstert.2019.07.1349

14. MacKintosh ML, Crosbie EJ. "Prevention Strategies in Endometrial Carcinoma." Curr Oncol Rep. 2018;20(12):101. doi:10.1007/s11912-018-0747-1

15. Webb PM, Na R, Weiderpass E, et al. "Use of Aspirin, Other Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen and Risk of Endometrial Cancer: The Epidemiology of Endometrial Cancer Consortium." Ann Oncol. 2019;30(2):310–316. doi:10.1093/annonc/mdy541

16. Shen S, Brown KA, Green AK, Iyengar NM. "Obesity and Cancer." JAMA. 2026. doi:10.1001/jama.2026.1114

17. Fatahichegeni M, Haji Ghasem Sharbatdar Z, Ansarian MA. "Advances in Endometrial Cancer Screening: A Comprehensive Review of Current Methods and Emerging Technologies." Int J Clin Oncol. 2025. doi:10.1007/s10147-025-02941-9

18. Asaturova A, Zaretsky A, Rogozhina A, Tregubova A, Badlaeva A. "Advancements in Minimally Invasive Techniques and Biomarkers for the Early Detection of Endometrial Cancer: A Comprehensive Review of Novel Diagnostic Approaches and Clinical Implications." J Clin Med. 2024;13(24):7538. doi:10.3390/jcm13247538

19. Cai Y, Chen S, Wu Z, et al. "Systematic Multiplatform Discovery of Methylation Markers Enables Non-Invasive Early Detection of Endometrial Cancer." Cancer Sci. 2026. doi:10.1111/cas.70346

20. Zhang T, Zhang P, Zhu L, et al. "Unlocking the Potential of Serum Exosomal PIWI-interacting RNAs as Diagnostic Biomarker for Endometrial Cancer." Int J Gynecol Cancer. 2026;36(5):104659. doi:10.1016/j.ijgc.2026.104659

21. Zhou L, Wang W, Wang F, et al. "Plasma-Derived Exosomal miR-15a-5p as a Promising Diagnostic Biomarker for Early Detection of Endometrial Carcinoma." Mol Cancer. 2021;20(1):57. doi:10.1186/s12943-021-01352-4

22. Cooley V, Fortner RT, Mukama T, et al. "Prospective Evaluation of 92 Protein Biomarkers for Early Detection of Endometrial Cancer." Int J Cancer. 2025;157(3):480–489. doi:10.1002/ijc.35428

23. American College of Obstetricians and Gynecologists. Tamoxifen and Uterine Cancer. ACOG Committee Opinion; 2018.